Acarix presents at Redeye: Commercialization Seminar
On March 7 at 10.30 CET Helen Ljungdahl Round, CEO of Acarix, presents the latest developments in the company at Redeye.The presentatio...
Acarix to showcase at the 2023 ACC congress
Acarix, a leader in acoustic and AI-based cardiac diagnostics, will demonstrate the value of its CADScor System during the American Col...
Acarix receives breakthrough order from US Veterans Health Administration
Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces today the first order from the US Veterans Health Administrati...
Acarix AB (publ) publishes Year-End Report 2022
Strategic shift towards full commercial focus on the US market now in placeAs we sum up 2022, it becomes clear that Acarix has in a sho...
ACARIX strengthens US Commercial Team
Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces today the appointment of two additional members of the Acarix ...
Invitation to presentation of Acarix´s fourth quarter report
Acarix will publish its fourth quarter results on Thursday 16 February 2023 at 08.00 am (CEST). A live webcast will be held at 11.00 (C...
Acarix is attending 2023 BIO CEO & Investor Conference in New York City
Acarix, a leader in innovative acoustic and AI-based cardiac diagnostics, will be attending for the first time the 25th annual BIO CEO ...
Acarix announces last day of trading with BTU and first day of trading in warrants
THIS ANNOUNCEMENT IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, C...
Acarix carries out a directed issue of shares to guarantors in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
Acarix announces final outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
Acarix publish supplement to prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
The guarantee consortium is expanded to cover approximately 62% of the ongoing rights issue in Acarix
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...